AHPA Issues Members New DMAA Rule
Beginning January 13, 2012, AHPA members may not label the ingredient DMAA as "geranium oil" or as being any part of the geranium plant.
The American Herbal Products Association’s (AHPA; Silver Spring, MD) Board of Trustees has issued a trade requirement to AHPA members regarding labeling of products containing 1,3-dimethylamylamine, also known as DMAA. Beginning January 13, 2012, AHPA members may not label the ingredient DMAA as “geranium oil” or as being any part of the geranium plant (e.g. “geranium oil,” “geranium stem,” “geranium extract”), either by common or botanical name. However, the requirement does not prevent the “geranium” labeling of any compound that is in fact derived from geranium plant materials.
DMAA was an inhaled nasal-decongestant drug by Eli Lilly in 1971, known as Forthane, and it has been used in weight-loss and bodybuilding dietary supplements. The association says it is still reviewing evidence to determine whether DMAA is in fact a constituent of the geranium species Pelargonium spp.
“There are no known-published reports indicating that [DMAA] is a natural product,” stated Steven Dentali, PhD, AHPA’s chief science officer. “Any labeling stating that it is naturally occurring in geranium, or any other natural source, would need appropriate scientific evidence to support it.”
The Nutritional Outlook Podcast Episode 39: Nutritional Outlook's Ingredients to Watch in 2025
February 25th 2025In this episode, Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2025.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
